Skip to content

stablishment of an Early Multimodal Neurological Function Prediction Model and Investigation of the Therapeutic Mechanisms of Mesenchymal Stem Cells in Post-Cardiac Arrest Brain Injury

stablishment of an Early Multimodal Neurological Function Prediction Model and Investigation of the Therapeutic Mechanisms of Mesenchymal Stem Cells in Post-Cardiac Arrest Brain Injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116742
Enrollment
Unknown
Registered
2026-01-14
Start date
2026-01-14
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest

Interventions

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years 2.Cardiac arrest (out-of-hospital or in-hospital), confirmed by documentation 3.Return of Spontaneous Circulation (ROSC) = 20 minutes (defined as sustained ROSC) 4.Informed consent obtained: The patient’s authorized representative provides consent within 24 hours after ROSC (if immediate signing is not possible, the deferred consent process approved by the center’s ethics committee will be followed)

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2. Cardiac arrest caused by organic diseases of the central nervous system (e.g., cerebral hemorrhage, ischemic stroke, brain herniation, etc.) 3. Patients with traumatic brain injury; history of severe neurological diseases (e.g., dementia, sequelae of stroke) 4.Terminal illnesses, such as end-stage malignant tumors 5. Early treatment limitation: Planned withdrawal of life support within 24 hours of admission for reasons unrelated to neurological prognosis (e.g., refractory multiple organ failure, indicators of treatment futility) 6.Inability to perform timely blood sampling/follow-up 7.Conditions that may severely interfere with the interpretation of biomarkers (e.g., active infectious/inflammatory central nervous system disease at admission, significant hemolysis rendering samples unusable)

Design outcomes

Primary

MeasureTime frame
Cerebral Performance Category,CPC;

Secondary

MeasureTime frame
Cerebral Performance Category,CPC;30-day mortality rate;

Countries

China

Contacts

Public ContactHuadong Zhu

Peking Union Medical College Hospital

zhuhuadong1970@126.com+86 10 6915 9142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026